Allen Seylani: Impact of a Treat-to-Target Urate-Lowering Strategy on Cardiovascular Events
Allen Seylani, Scientific Reviewer at Oxford University Press, Resident Physician at Cleveland Clinic, shared a post on LinkedIn about a recent article by Pascal Richette et al. published in JAMA Internal Medicine:
“A new study in JAMA Internal Medicine followed over 100,000 patients with gout and asked a simple but powerful question.
Does treating to a serum urate target below 6 mg/dL actually change cardiovascular outcomes.
The answer appears to be yes.
Patients who achieved target urate levels had a significantly lower risk of major cardiovascular events within 5 years compared with those who did not.
Fewer flares were expected. Fewer heart attacks and strokes were not.
This matters because it reframes gout from a nuisance disease to a systemic inflammatory condition with real cardiovascular consequences. It also challenges us as clinicians and researchers to stop thinking of urate lowering as a checkbox and start thinking of it as disease modification.
The most striking part to me is not just the association, but the implication. Inflammation, not urate alone, may be the missing link connecting gout to cardiovascular risk. Treating to target likely works because it quiets chronic inflammation, reduces flare related inflammatory surges, and stabilizes the system as a whole.
And yet, fewer than one third of patients actually reached target urate levels within a year.
That gap between evidence and practice is where leadership lives.
This is where better care models, tighter follow up, patient education, and accountability can change outcomes at scale. It is also where translational thinking matters, connecting population data, molecular inflammation, and bedside decisions.
Gout is no longer just about pain control. It is about prevention, longevity, and systems level thinking.
Curious how others are integrating treat to target strategies into real world practice, and how we can do better for patients who are still being left behind.”
Title: Urate Lowering and Cardiovascular Risk—Extending the Benefits of a Treat-to-Target Strategy in Gout
Authors: Pascal Richette, Augustin Latourte, Hang-Korng Ea
Read the Full Article on JAMA Internal Medicine

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines